Achieve Life Sciences Inc
NASDAQ:ACHV

Watchlist Manager
Achieve Life Sciences Inc Logo
Achieve Life Sciences Inc
NASDAQ:ACHV
Watchlist
Price: 3.77 USD -1.31%
Market Cap: 129.5m USD
Have any thoughts about
Achieve Life Sciences Inc?
Write Note

Achieve Life Sciences Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Achieve Life Sciences Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Achieve Life Sciences Inc
NASDAQ:ACHV
Accounts Payable
$1m
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$4B
CAGR 3-Years
215%
CAGR 5-Years
112%
CAGR 10-Years
59%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%
No Stocks Found

Achieve Life Sciences Inc
Glance View

Market Cap
129.7m USD
Industry
Biotechnology

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).

ACHV Intrinsic Value
5.1 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Achieve Life Sciences Inc's Accounts Payable?
Accounts Payable
1m USD

Based on the financial report for Sep 30, 2024, Achieve Life Sciences Inc's Accounts Payable amounts to 1m USD.

What is Achieve Life Sciences Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-4%

Over the last year, the Accounts Payable growth was 69%. The average annual Accounts Payable growth rates for Achieve Life Sciences Inc have been 8% over the past three years , 11% over the past five years , and -4% over the past ten years .

Back to Top